SCHEMBL351229

SCHEMBL351229

O=C1OC2(CCN(C(=O)C3(c4ccc(N5CCN(C(=O)C6CCOCC6)CC5)cc4)CC3)C2)c2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 17/20 0.64
CYP2D6 P10635 1/20 0.64
NPY5R Q15761 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348803 1.00 HSD11B1 (0.64) HSD11B1CYP2D6NPY5RMAPTCYP2C9
SCHEMBL1319734 0.96 HSD11B1 (0.67) HSD11B1CYP2D6NPY5R
SCHEMBL351520 0.96 HSD11B1 (0.67) HSD11B1CYP2D6NPY5R
SCHEMBL351798 0.93 HSD11B1 (0.63) HSD11B1CYP2D6NPY5R
SCHEMBL351673 0.93 HSD11B1 (0.63) HSD11B1CYP2D6NPY5R
SCHEMBL351552 0.88 HSD11B1 (0.74) HSD11B1CYP2D6NPY5R
SCHEMBL351256 0.88 HSD11B1 (0.74) HSD11B1CYP2D6NPY5R
SCHEMBL348502 0.86 HSD11B1 (0.71) HSD11B1CYP2D6NPY5R
SCHEMBL350567 0.86 HSD11B1 (0.71) HSD11B1CYP2D6NPY5R
SCHEMBL348715 0.86 HSD11B1 (0.70) HSD11B1CYP2D6NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963021-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Holdings Corporation (US) 2016-01-06 EP claimed
US-20150329561-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION 2015-11-19 US claimed
US-9126927-B2 Amido compounds and their use as pharmaceuticals INCYTE HOLDINGS CORPORATION (US) 2015-09-08 US claimed
EP-1756063-B1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2015-07-08 EP claimed
US-20120015928-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION (US) 2012-01-19 US claimed
US-8058288-B2 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2011-11-15 US claimed
US-20100256114-A1 Amido Compounds And Their Use As Pharmaceuticals INCYTE CORPORATION (US) 2010-10-07 US claimed
US-7304081-B2 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2007-12-04 US claimed
US-20070179142-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-02 US claimed
US-20050282858-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-22 US claimed
EP-2963021-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Holdings Corporation (US) 2016-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256114-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885
US-20050282858-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885
US-20120015928-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885
US-20150329561-A1 Amido Compounds And Their Use As Pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885
US-20070179142-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.